Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)

NCT00494299 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

458

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: Sorafenib (Nexavar, BAY43-9006)
DRUG: Placebo

Sponsor

Bayer